Stockreport

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China an [Read more]